Kiniksa Pharmaceuticals International, plc (KNSA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Kiniksa Pharmaceuticals International reported revenue of $677.6M, up 60.1% from $423.2M the year before. Net income was $59.0M (a 8.7% net margin), or $0.75 per diluted share. Gross margin was 88.5% and operating margin was 11.4%. Operating activities generated $138.0M of cash, leaving $136.4M of free cash flow. At fiscal year end, Kiniksa Pharmaceuticals International held $763.6M in total assets against $196.0M in total liabilities, including $165.6M of cash and equivalents.
Open the full interactive Kiniksa Pharmaceuticals International financials → Quarterly statements, key ratios, valuation history and price charts.
Kiniksa Pharmaceuticals International Key Stats
| Share Price | $78.53 |
|---|---|
| Market Cap | $6.55B |
| P/E Ratio | 104.7 |
| Revenue YoY Growth | +60.1% |
| 52-Week Range | $37.01 – $80.92 |
| Shares Outstanding | 77.6 million (basic, 2026 Q2) |
Kiniksa Pharmaceuticals International Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $38.5M | $220.2M | $270.3M | $423.2M | $677.6M |
| Cost of Goods Sold | — | $9.1M | $22.9M | $33.4M | $60.9M | $77.7M |
| Gross Profit | — | $29.4M | $197.3M | $236.9M | $362.3M | $599.9M |
| Operating Income | -$157.4M | -$156.6M | $9.8M | -$25.2M | -$45.6M | $77.2M |
| Pre-Tax Income | -$156.2M | -$156.5M | $11.0M | -$16.7M | -$36.2M | $88.9M |
| Income Tax | $5.2M | $1.4M | -$172.3M | -$30.7M | $7.0M | $29.9M |
| Net Income | -$161.4M | -$157.9M | $183.4M | $14.1M | -$43.2M | $59.0M |
| Diluted EPS | -$2.61 | -$2.30 | $2.60 | $0.20 | -$0.60 | $0.75 |
Kiniksa Pharmaceuticals International Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $180.9M | $202.1M | $214.3M | $243.6M |
| Net Income | $18.4M | $14.2M | $22.6M | $25.4M |
| Diluted EPS | $0.23 | $0.18 | $0.27 | $0.30 |
Kiniksa Pharmaceuticals International Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $114.0M | $122.5M | $122.7M | $108.0M | $183.6M | $165.6M |
| Current Assets | $333.2M | $196.4M | $243.1M | $276.3M | $331.8M | $527.2M |
| Total Assets | $349.5M | $232.8M | $459.7M | $526.3M | $580.6M | $763.6M |
| Current Liabilities | $31.8M | $44.8M | $47.1M | $63.7M | $100.6M | $139.2M |
| Total Liabilities | $37.5M | $47.8M | $63.5M | $87.5M | $142.1M | $196.0M |
| Shareholders' Equity | $311.9M | $185.0M | $396.1M | $438.8M | $438.4M | $567.6M |
Kiniksa Pharmaceuticals International Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$136.5M | -$126.3M | $5.8M | $13.3M | $25.7M | $138.0M |
| Cash From Investing | -$23.4M | $128.6M | -$8.1M | -$29.6M | $37.7M | -$189.0M |
| Cash From Financing | $227.1M | $5.9M | $2.5M | $1.5M | $12.3M | $33.0M |
| Free Cash Flow | -$136.8M | -$126.7M | $5.7M | $13.2M | $25.4M | $136.4M |
Figures from Kiniksa Pharmaceuticals International's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Kiniksa Pharmaceuticals International financials page for every line item.
Kiniksa Pharmaceuticals International Company Profile
| Ticker | KNSA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | London |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001730430 |
Frequently Asked Questions
What was Kiniksa Pharmaceuticals International's revenue in fiscal 2025?
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $677.6M for fiscal 2025.
What is Kiniksa Pharmaceuticals International's annual revenue history?
Kiniksa Pharmaceuticals International's annual revenue by fiscal year: 2020: $0; 2021: $38.5M; 2022: $220.2M; 2023: $270.3M; 2024: $423.2M; 2025: $677.6M.
What was Kiniksa Pharmaceuticals International's net income in fiscal 2025?
Kiniksa Pharmaceuticals International reported net income of $59.0M for fiscal 2025.
What was Kiniksa Pharmaceuticals International's earnings per share (EPS) in fiscal 2025?
Kiniksa Pharmaceuticals International's diluted EPS was $0.75 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Kiniksa Pharmaceuticals International generate in fiscal 2025?
Kiniksa Pharmaceuticals International generated $136.4M of free cash flow in fiscal 2025.
What was Kiniksa Pharmaceuticals International's revenue last quarter?
In its most recent reported quarter (2026 Q2), Kiniksa Pharmaceuticals International reported revenue of $243.6M.
How many shares of Kiniksa Pharmaceuticals International are outstanding?
Kiniksa Pharmaceuticals International reported a weighted average of 77.6 million basic shares outstanding in 2026 Q2.
What is Kiniksa Pharmaceuticals International's market cap?
Based on its latest closing price, Kiniksa Pharmaceuticals International (KNSA) has a market capitalization of about $6.55B.
When does Kiniksa Pharmaceuticals International's fiscal year end?
Kiniksa Pharmaceuticals International's fiscal year end, as registered with the SEC, is December 31.
Where is Kiniksa Pharmaceuticals International headquartered?
Kiniksa Pharmaceuticals International lists its business address in London in its SEC filings.